Neopterin: A Potential Biomarker for Delirium in Elderly Patients

Angelique Egberts, Eline Wijnbeld, Durk Fekkes, Milly Ploeg, Bert Ziere, H (Herbert) Hooijkaas, T.J.M. van der Cammen, F.U.S. Mattace Raso

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Scopus)


Background/Aims: The diagnosis of delirium is not supported by specific biomarkers. In a previous study, high neopterin levels were found in patients with a postoperative delirium. In the present study, we investigated levels of neopterin, interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) in acutely ill admitted elderly patients with and without a delirium. Methods: Plasma/serum levels of neopterin, IL-6 and IGF-1 were determined in patients aged >= 65 years admitted to the wards of Internal Medicine and Geriatrics. Differences in biomarker levels between patients with and without a delirium were investigated by the analysis of variance in models adjusted for age, gender, comorbidities and eGFR (when appropriate). Results: Eighty-six patients were included; 23 of them with a delirium. In adjusted models, higher mean levels of neopterin (70.5 vs. 45.9 nmol/l, p = 0.009) and IL-6 (43.1 vs. 18.5 pg/ml, p = 0.034) and lower mean levels of IGF-1 (6.3 vs. 9.3 nmol/l, p = 0.007) were found in patients with a delirium compared to those without. Conclusions: The findings of this study suggest that neopterin might be a potential biomarker for delirium which, through oxidative stress and activation of the immune system, may play a role in the pathophysiology of delirium. (C) 2014 S. Karger AG, Basel.
Original languageUndefined/Unknown
Pages (from-to)116-124
Number of pages9
JournalDementia and Geriatric Cognitive Disorders
Issue number1-2
Publication statusPublished - 2015

Cite this